Format

Send to

Choose Destination
Obstet Gynecol. 2010 Apr;115(4):727-33. doi: 10.1097/AOG.0b013e3181d57b09.

Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid.

Author information

1
Service de Parasitologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. martine.wallon@chu-lyon.fr

Abstract

OBJECTIVE:

To provide clinicians with information about the accuracy of real-time polymerase chain reaction (PCR) analysis of amniotic fluid for the prenatal diagnosis of congenital Toxoplasma infection.

METHODS:

This was a prospective cohort study of women with Toxoplasma infection identified by prenatal screening in three centers routinely carrying out real-time PCR for the detection of Toxoplasma gondii in amniotic fluid. The data available were gestational age at maternal infection, types and dates of maternal treatment, results of amniocentesis and neonatal work-up and definitive infectious status of the child. We estimated sensitivity, specificity and positive and negative predictive values both overall and per trimester of pregnancy at the time of maternal infection.

RESULTS:

Polymerase chain reaction analysis was carried out on amniotic fluid for 261 of the 377 patients included (69%). It was accurate with the exception of four negative results in children who were infected. Overall sensitivity and negative predictive value were 92.2% (95% confidence interval [CI] 81-98%) and 98.1% (95% CI 95-99.5%), respectively. There was no significant association with the trimester of pregnancy during which maternal infection occurred. Specificity and positive predictive values of 100% were obtained for all trimesters.

CONCLUSION:

Real-time PCR analysis significantly improves the detection of T. gondii on amniotic fluid. It provides an accurate tool to predict fetal infection and to decide on appropriate treatment and surveillance. However, postnatal follow-up remains necessary in the first year of life to fully exclude infection in children for whom PCR results were negative.

LEVEL OF EVIDENCE:

III.

PMID:
20308831
DOI:
10.1097/AOG.0b013e3181d57b09
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center